Morgan Stanley
TEVA icon

Morgan Stanley’s Teva Pharmaceuticals TEVA Stock Holding History

Morgan Stanley’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236M Sell
6,968,719
-457,534
-6% -$15.2M 0.01% 920
2026
Q1 		$224M Sell
7,426,253
-1,018,548
-12% -$32.8M 0.01% 889
2025
Q4 		$264M Buy
8,444,801
+1,969,783
+30% +$48.5M 0.02% 795
2025
Q3 		$131M Sell
6,475,018
-138,535
-2% -$2.43M 0.01% 1192
2025
Q2 		$111M Sell
6,613,553
-4,384,373
-40% -$70.7M 0.01% 1240
2025
Q1 		$169M Sell
10,997,926
-3,913,193
-26% -$69.9M 0.01% 937
2024
Q4 		$329M Buy
14,911,119
+1,355,226
+10% +$24.7M 0.02% 626
2024
Q3 		$244M Buy
13,555,893
+416,691
+3% +$7.29M 0.02% 728
2024
Q2 		$214M Buy
13,139,202
+7,713,582
+142% +$119M 0.02% 774
2024
Q1 		$76.6M Sell
5,425,620
-2,799,460
-34% -$35.3M 0.01% 1378
2023
Q4 		$85.9M Buy
8,225,080
+2,416,602
+42% +$22.6M 0.01% 1269
2023
Q3 		$59.2M Sell
5,808,478
-1,141,312
-16% -$10.6M 0.01% 1419
2023
Q2 		$52.3M Buy
6,949,790
+2,080,202
+43% +$16.9M 0.01% 1543
2023
Q1 		$43.1M Sell
4,869,588
-1,424,405
-23% -$14.1M ﹤0.01% 1681
2022
Q4 		$57.4M Buy
6,293,993
+465,489
+8% +$4.06M 0.01% 1386
2022
Q3 		$47M Sell
5,828,504
-42,419
-0.7% -$375K 0.01% 1356
2022
Q2 		$44.1M Buy
5,870,923
+1,993,556
+51% +$17.4M 0.01% 1470
2022
Q1 		$36.4M Buy
3,877,367
+295,320
+8% +$2.46M ﹤0.01% 1533
2021
Q4 		$28.7M Buy
3,582,047
+928,791
+35% +$8.38M ﹤0.01% 1789
2021
Q3 		$25.8M Buy
2,653,256
+279,384
+12% +$2.62M ﹤0.01% 1818
2021
Q2 		$23.5M Buy
2,373,872
+531,663
+29% +$5.63M ﹤0.01% 1984
2021
Q1 		$21.3M Sell
1,842,209
-665,746
-27% -$7.63M ﹤0.01% 1850
2020
Q4 		$24.2M Buy
2,507,955
+14,762
+0.6% +$141K ﹤0.01% 1626
2020
Q3 		$22.5M Sell
2,493,193
-131,796
-5% -$1.39M ﹤0.01% 1392
2020
Q2 		$32.4M Sell
2,624,989
-234,039
-8% -$2.65M 0.01% 1092
2020
Q1 		$25.7M Sell
2,859,028
-2,732,117
-49% -$28M 0.01% 1112
2019
Q4 		$54.8M Buy
5,591,145
+2,084,109
+59% +$18.6M 0.01% 872
2019
Q3 		$24.1M Sell
3,507,036
-3,498,317
-50% -$26.8M 0.01% 1350
2019
Q2 		$64.7M Buy
7,005,353
+5,140,764
+276% +$62M 0.02% 725
2019
Q1 		$29.2M Buy
1,864,589
+290,110
+18% +$5.12M 0.01% 1168
2018
Q4 		$24.3M Sell
1,574,479
-1,148,742
-42% -$23.6M 0.01% 1295
2018
Q3 		$58.7M Sell
2,723,221
-1,836,111
-40% -$42.6M 0.01% 863
2018
Q2 		$111M Buy
4,559,332
+729,283
+19% +$14.9M 0.03% 527
2018
Q1 		$65.5M Sell
3,830,049
-2,593,449
-40% -$50.6M 0.02% 777
2017
Q4 		$122M Buy
6,423,498
+230,685
+4% +$3.47M 0.03% 516
2017
Q3 		$109M Sell
6,192,813
-819,573
-12% -$18.4M 0.03% 525
2017
Q2 		$233M Sell
7,012,386
-1,491,530
-18% -$46.2M 0.07% 294
2017
Q1 		$273M Buy
8,503,916
+1,302,307
+18% +$44.4M 0.08% 251
2016
Q4 		$261M Sell
7,201,609
-1,536,705
-18% -$61.4M 0.09% 261
2016
Q3 		$402M Buy
8,738,314
+5,935,210
+212% +$310M 0.14% 155
2016
Q2 		$141M Sell
2,803,104
-226,850
-7% -$12.1M 0.05% 406
2016
Q1 		$162M Buy
3,029,954
+1,416,525
+88% +$83.1M 0.06% 336
2015
Q4 		$106M Buy
1,613,429
+15,631
+1% +$966K 0.04% 467
2015
Q3 		$90.2M Sell
1,597,798
-499,766
-24% -$32.4M 0.03% 513
2015
Q2 		$124M Sell
2,097,564
-106,352
-5% -$6.56M 0.04% 436
2015
Q1 		$137M Buy
2,203,916
+475,332
+27% +$27.6M 0.05% 399
2014
Q4 		$99.4M Sell
1,728,584
-243,391
-12% -$13.6M 0.04% 521
2014
Q3 		$106M Buy
1,971,975
+204,458
+12% +$10.8M 0.04% 492
2014
Q2 		$92.7M Buy
1,767,517
+35,675
+2% +$1.82M 0.04% 540
2014
Q1 		$91.5M Sell
1,731,842
-1,002,438
-37% -$46.3M 0.04% 508
2013
Q4 		$110M Buy
2,734,280
+304,759
+13% +$12M 0.05% 421
2013
Q3 		$91.8M Buy
2,429,521
+43,777
+2% +$1.71M 0.04% 446
2013
Q2 		$93.5M Buy
+2,385,744
New +$92.9M 0.05% 427

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Morgan Stanley's TEVA Position: Q2 2026 in Review

Morgan Stanley reduced its Teva Pharmaceuticals (TEVA) stake by 6.2% in Q2 2026, selling an estimated $15.2M and leaving 6,968,719 shares worth $236M. The position accounts for 0.01% of the portfolio, ranked #920.

Morgan Stanley first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $402M in Q3 2016. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Morgan Stanley held 6,968,719 shares of Teva Pharmaceuticals worth $236M as of Q2 2026.
  • Morgan Stanley sold 457,534 Teva Pharmaceuticals shares in Q2 2026, an estimated $15.2M.
  • Teva Pharmaceuticals made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #920 holding.
  • Morgan Stanley first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Morgan Stanley's Teva Pharmaceuticals position peaked at $402M in Q3 2016.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.